Primary outcome indices in illicit drug dependence treatment research: Systematic approach to selection and measurement of drug use end-points in clinical trials

Addiction

Volumn 107, Issue 4, 2012, Pages 694-708

  Donovan, Dennis M ^a   Bigelow, George E ^b   Brigham, Gregory S ^c,m   Carroll, Kathleen M ^d   Cohen, Allan J ^e   Gardin, John G ^f   Hamilton, John A ^g   Huestis, Marilyn A ^h   Hughes, John R ⁱ   Lindblad, Robert ^j   Marlatt, G Alan ^k   Preston, Kenzie L ^h   Selzer, Jeffrey A ^l   Somoza, Eugene C ^m   Wakim, Paul G ^h   Wells, Elizabeth A ^k  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Maryhaven   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Bay Area Addiction Research and Treatment   (United States)

^f Adapt Inc   (United States)

^g Regional Network of Programs Inc   (United States)

^h NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

ⁱ UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^j EMMES CORPORATION   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l University of Cincinnati ^*  (United States)

^m UNIVERSITY OF CINCINNATI   (United States)

more..

Author keywords

Clinical trials; Drug dependence; End points; Primary outcome; Self report; Toxicology; Treatment research

Indexed keywords

STREET DRUG;

ADDICTION; ALCOHOLISM; ARTICLE; BIOASSAY; CLINICAL TRIAL (TOPIC); CONSENSUS; HUMAN; MEDICAL RESEARCH; METHODOLOGY; SELF REPORT; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ALCOHOLISM; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONSENSUS; ENDPOINT DETERMINATION; HUMANS; SELF REPORT; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84857576135     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03473.x     Document Type: Article

References (100)

1. Wells E. A., Saxon A. J., Calsyn D. A., Jackson T. R., Donovan D. M. Study results from the Clinical Trials Network's first 10 years: where do they lead? J Subst Abuse Treat 2010; 38: S14-30.
2. Wells E. A., Hawkins J. D., Catalano R. F. Jr. Choosing drug use measures for treatment outcome studies. I. The influence of measurement approach on treatment results. Int J Addict 1988; 23: 851-73.
3. Wells E. A., Hawkins J. D., Catalano R. F. Jr. Choosing drug use measures for treatment outcome studies. II. Timing baseline and follow-up measurement. Int J Addict 1988; 23: 875-85.
4. Van den Brink W., Montgomery S. A., Van Ree J. M., van Zwieten-Boot B. J. On behalf of the Consensus Committee. ECNP Consensus Meeting March 2003: guidelines for the investigation of efficacy in substance use disorders. Eur Neuropsychopharmacol 2006; 16: 224-30.
5. Marsden J., Nizzoli U., Corbelli C., Margaron H., Torres M., Prada De Castro I. etal. New European instruments for treatment outcome research: reliability of the maudsley addiction profile and treatment perceptions questionnaire in Italy, Spain and Portugal. Eur Addict Res 2000; 6: 115-22.
6. Donovan D. M., Marlatt G. A. Assessment of Addictive Behaviors. New York: Guilford Press; 1988.
7. Donovan D. M., Marlatt G. A., editors. Assessment of Addictive Behaviors, 2nd edn. New York: Guilford Press; 2005.
8. McLellan A. T., Chalk M., Bartlett J. Outcomes, performance, and quality: what's the difference? J Subst Abuse Treat 2007; 32: 331-40.
9. Substance Abuse and Mental Health Services Administration. A report required by Congress on performance partnerships: a discussion of SAMHSA's efforts to increase accountability based on performance in its Block Grant Programs by instituting National Outcome Measures. Substance Abuse and Mental Health Services Administration, editor. Rockville, MD, 2004.
10. Darke S., Hall W., Wodak A., Heather N., Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992; 87: 733-42.
11. Marsden J., Gossop M., Stewart D., Best D., Farrell M., Lehmann P. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction 1998; 93: 1857-68.
12. Dole V. P., Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965; 193: 646-50.
13. Miller W. R., Manuel J. K. How large must a treatment effect be before it matters to practitioners? An estimation method and demonstration. Drug Alcohol Rev 2008; 27: 524-8.
14. Laudet A. B., Becker J. B., White W. L. Don't wanna go through that madness no more: quality of life satisfaction as predictor of sustained remission from illicit drug misuse. Subst Use Misuse 2009; 44: 227-52.
15. Miller P. G., Miller W. R. What should we be aiming for in the treatment of addiction? Addiction 2009; 104: 685-6.
16. Rounsaville B. J., Petry N. M., Carroll K. M. Single versus multiple drug focus in substance abuse clinical trials research. Drug Alcohol Depend 2003; 70: 117-25.
17. Kellogg S. H. On 'Gradualism' and the building of the harm reduction-abstinence continuum. J Subst Abuse Treat 2003; 25: 241-7.
18. Marlatt G. A., Witkiewitz K. Update on harm-reduction policy and intervention research. Annu Rev Clin Psychol 2010; 27: 591-606.
19. Miller W. R., LoCastro J. S., Longabaugh R., O'Malley S., Zweben A. When worlds collide: blending the divergent traditions of pharmacotherapy and psychotherapy outcome research. J Stud Alcohol 2005; (suppl): 17-23.
20. Tai B. Workshop summary: Outcome measures and success criteria. In: Tai B., Chiang N., Bridge P., editors. Medication development for the treatment of cocaine dependence: Issues in clinical efficacy trials. NIDA Research Monograph 175; 2008. Rockville, MD: National Institutes of Health, National Institute on Drug Abuse, Office of Science Policy and Communications. p. 303-11. Available from (accessed 21 June 2011; archived by Webcite at )
21. Vocci F., de Wit H. Consensus statement on evaluation of outcome of pharmacotherapy for substance abuse/dependence: report from a NIDA/CPDD meeting. In: National Institute on Drug Abuse Medications Development Division. Bethesda, MD, 1999. Available from: (accessed 17 June 2011; archived by Webcite at )
22. Aveyard P., Wang D., Connock M., Fry-Smith A., Barton P., Moore D. Assessing the outcomes of prolonged cessation-induction and aid-to-cessation trials: floating prolonged abstinence. Nicotine Tob Res 2009; 11: 475-80.
23. Hughes J. R. Measurements of the effects of abstinence from tobacco. A qualitative reiview. Psychol Addict Behav 2007; 21: 127-37.
24. West R., Hajek P., Stead L., Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303.
25. Shiffman S., West R. J., Gilbert D. G. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res 2004; 6: 599-614.
26. Hughes J. R., Keely J., Niaura R., Ossip-Klein D., Richmond R., Swan G. Measures of abstinence from tobacco in clinical trials: issues and recommendations. Nicotine Tob Res 2003; 5: 13-25.
27. Society for Research on Nicotine and Tobacco Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002; 4: 149-59.
28. Hughes J. R. Should criteria for drug dependence vary across drugs? Addiction 2006; 101: S134-41.
29. Shiffman S., Scharf D., Shadel W., Gwaltney C., Dang Q., Paton S. etal. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol 2006; 74: 276-85.
30. Velicer W. F., Prochaska J. O., Rossi J. S., Snow M. G. Assessing outcome in smoking cessation studies. Psychol Bull 1992; 111: 23-41.
31. Hughes J., Carpenter M., Naud S. Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review. Nicotine Tob Res 2010; 12: 756-62.
32. Velicer W. F., Prochaska J. O. A comparison of four smoking cessation outcome measures. Addict Behav 2004; 29: 51-60.
33. Shiffman S. How many cigarettes did you smoke? Assessing cigarette consumption by global report, time-line follow-back, and ecological momentary assessment. Health Psychol 2009; 28: 519-26.
34. Klesges R. C., Debon M., Ray J. W. Are self-reports of smoking rate biased? Evidence from the second national health and nutrition examination survey. J Clin Epidemiol 1995; 48: 1225-33.
35. Hughes J. R. Observer reports of smoking status: a replication. J Subst Abuse 1993; 4: 403-6.
36. National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much: a clinician's guide. In: National Institutes of Health. Updated 2005 edition. Bethesda, MD: US Government Printing Office; 2007. Available from: (accessed 17 June 2011; archived by Webcite at )
37. National Institute on Alcohol Abuse and Alcoholism. Rethinking drinking: alcohol and your health. In: National Institutes of Health. Bethesda, MD: US Government Printing Office; 2010. Available from (accessed 17 June 2011; archived by Webcite at )
38. Institute of Alcohol Studies (IAS). IAS fact sheet: what is problem drinking? In: Institute of Alcohol Studies, editor. St Ives, Cambridgeshire, UK, 2002.
39. Babor T. F., Higgins-Biddle J. C., Saunders J. B., Monteiro M. G. AUDIT: The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Care, 2nd edn. Geneva: World Health Organization; 2001.
40. Devos-Comby L., Lange J. E. 'My drink is larger than yours'? A literature review of self-defined drink sizes and standard drinks. Curr Drug Abuse Rev 2008; 1: 162-76.
41. Kaskutas L. A., Graves K. An alternative to standard drinks as a measure of alcohol consumption. J Subst Abuse 2000; 12: 67-78.
42. Kerr W. C., Greenfield T. K., Tujague J., Brown S. E. A drink is a drink? Variation in the amount of alcohol contained in beer, wine and spirits drinks in a US methodological sample. Alcohol Clin Exp Res 2005; 29: 2015-21.
43. Miller W. R., Heather N., Hall W. Calculating standard drink units: international comparisons. Br J Addict 1991; 86: 43-7.
44. Allen J. P. Measuring outcome in interventions for alcohol dependence and problem drinking: executive summary of a conference sponsored by the National Institute on Alcohol Abuse and Alcoholism. Alcohol Clin Exp Res 2003; 27: 1657-60.
45. Falk D., Wang X. Q., Liu L., Fertig J., Mattson M., Ryan M. etal. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res 2010; 34: 2022-34.
46. Finney J. W., Moyer A., Swearingen C. E. Outcome variables and their assessment in alcohol treatment studies: 1968-1998. Alcohol Clin Exp Res 2003; 27: 1671-9.
47. Litten R. Z., Bradley A. M., Moss H. B. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 2010; 34: 955-67.
48. Zweben A., Cisler R. A. Clinical and methodological utility of a composite outcome measure for alcohol treatment research. Alcohol Clin Exp Res 2003; 27: 1680-5.
49. Anton R. F., Randall C. L. Measurement and choice of drinking outcome variables in the COMBINE study. J Stud Alcohol 2005; (suppl): 104-9.
50. Sobell L. C., Sobell M. B. Timeline followback: a technique for assessing self-reported alcohol consumption. In: Litten R. Z., Allen J. P., editors. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press; 1992, p. 41-72.
51. Sobell L. C., Sobell M. B., Connors G. J., Agrawal S. Assessing drinking outcomes in alcohol treatment efficacy studies: selecting a yardstick of success. Alcohol Clin Exp Res 2003; 27: 1661-6.
52. Helander A., Bottcher M., Fehr C., Dahmen N., Beck O. Detection time of urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol 2009; 44: 55-61.
53. Goodwin R. S., Darwin W. D., Chiang C. N., Shih M., Li S.-H., Huestis M. A. Urinary elimination of 11-Nor-9-Carboxy-D9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008; 32: 562-6.
54. Huestis M. A., Cone E. J. Methamphetamine disposition in oal fluid, plasma, and urine. Ann NY Acad Sci 2007; 1098: 104-21.
55. Huestis M. A., Cone E. J., Wong C. J., Umbricht A., Preston K. L. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. J Anal Toxicol 2000; 24: 509-21.
56. Huestis M. A., Mitchell J. M., Cone E. J. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 1995; 19: 443-9.
57. Huestis M. A., Cone E. J. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 1998; 22: 445-54.
58. Smith M. L., Barnes A. J., Huestis M. A. Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol 2009; 33: 185-9.
59. Schwilke E. W., Gullberg R. G., Darwin W. D., Chiang N., Cadet J. L., Gorelick D. A. etal. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction 2010; 106: 499-506.
60. Preston K. L., Silverman K., Schuster C. R., Cone E. J. Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction 1997; 92: 717-27.
61. Center for Substance Abuse Treatment. The role of biomarkers in the treatment of alcohol use disorders. Subst Abuse Treat Advisory 2006; 5: 1-7.
62. Preston K. L., Huestis M. A., Wong C. J., Umbricht A., Goldberger B. A., Cone E. J. Monitoring cocaine use in substance abuse treatment patients by sweat and urine testing. J Anal Toxicol 1999; 23: 313-22.
63. Huestis M. A., Scheidweiler K. B., Saito T., Fortner N., Abraham T., Gustafson R. A. etal. Excretion of Delta9-tetrahydrocannabinol in sweat. Forensic Sci Int 2008; 174: 173-7.
64. Winhusen T. M., Somoza E. C., Singal B., Kim S., Horn P. S., Rotrosen J. Measuring outcome in cocaine clinical trials: a comparison of sweat patches with urine toxicology and participant self-report. Addiction 2003; 98: 317-24.
65. Dolan K., Rouen D., Kimber J. An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug Alcohol Rev 2004; 23: 213-7.
66. Rollins D. E., Wilkins D. G., Krueger G. G., Augsburger M. P., Mizuno A., O'Neal C. etal. The effect of hair color on the incorporation of codeine into human hair. J Anal Toxicol 2003; 27: 545-51.
67. Fauci A. S., Braunwald E., Isselbacher K. J., Wilson J. D., Martin J. B., Kasper D. L. etal., editors. Harrison's Principles of Internal Medicine, 14th edn. New York: McGraw-Hill, Health Professions Division; 1998.
68. Scheidweiler K. B., Huestis M. A. Simultaneous quantification of opiates, cocaine, and metabolites in hair by LC-APCI-MS/MS. Anal Chem 2004; 76: 4358-63.
69. DuPont R., Goldberger B., Gold M. Clinical and legal considerations in drug testing. In: Ries R., Fiellin D., Miller S., Saitz R., editors. Principles of Addiction Medicine, 4th edn. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2009, p. 1495-8.
70. Blank D. L., Kidwell D. A. External contamination of hair by cocaine: an issue in forensic interpretation. Forensic Sci Int 1993; 63: 145-56.
71. Wang W. L., Cone E. J. Testing human hair for drugs of abuse. IV. Environmental cocaine contamination and washing effects. Forensic Sci Int 1995; 70: 39-51.
72. Fals-Stewart W., O'Farrell T. J., Freitas T. T., McFarlin S. K., Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 2000; 68: 134-44.
73. Hersh D., Mulgrew C. L., Van Kirk J., Kranzler H. R. The validity of self-reported cocaine use in two groups of cocaine abusers. J Consult Clin Psychol 1999; 67: 37-42.
74. Napper L. E., Fisher D. G., Johnson M. E., Wood M. M. The validity and reliability of drug users' self reports of amphetamine use among primarily heroin and cocaine users. Addict Behav 2010; 35: 350-4.
75. Schuler M. S., Lechner W. V., Carter R. E., Malcolm R. Temporal and gender trends in concordance of urine drug screens and self-reported use in cocaine treatment studies. J Addict Med 2009; 3: 211-7.
76. Sherman M. F., Bigelow G. E. Validity of patients' self-reported drug use as a function of treatment status. Drug Alcohol Depend 1992; 30: 1-11.
77. Zanis D. A., McLellan A. T., Randall M. Can you trust patient self-reports of drug use during treatment? Drug Alcohol Depend 1994; 35: 127-32.
78. Ehrman R. N., Robbins S. J. Reliability and validity of 6-month timeline reports of cocaine and heroin use in a methadone population. J Consult Clin Psychol 1994; 62: 843-50.
79. Johnson M. B., Voas R. A., Miller B. A., Holder H. D. Predicting drug use at electronic music dance events: self-reports and biological measurement. Eval Rev 2009; 33: 211-25.
80. Magura S. Validating self-reports of illegal drug use to evaluate National Drug Control Policy: a reanalysis and critique. Eval Program Plann 2010; 33: 234-7.
81. Williams R. J., Nowatzki N. Validity of adolescent self-report of substance use. Subst Use Misuse 2005; 40: 299-311.
82. Babor T. F., Steinberg K., Anton R., Del Boca F. Talk is cheap: measuring drinking outcomes in clinical trials. J Stud Alcohol 2000; 61: 55-63.
83. Del Boca F. K., Noll J. A. Truth or consequences: the validity of self-report data in health services research on addictions. Addiction 2000; 95: S347-60.
84. Langenbucher J., Merrill J. The validity of self-reported cost events by substance abusers: limits, liabilities, and future directions. Eval Rev 2001; 25: 184-210.
85. Carey K. B. Reliability and validity of the time-line follow-back interview among psychiatric outpatients: a preliminary report. Psychol Addict Behav 1997; 11: 26-33.
86. Meyer T. D., Hautzinger M. Assessing current alcohol use with the Form 90 in a student sample. Psychol Psychother 2009; 82: 233-45.
87. Miller W. R., Del Boca F. K. Measurement of drinking behavior using the Form 90 family of instruments. J Stud Alcohol 1994; (suppl): 112-8.
88. Rice C. Retest reliability of self-reported daily drinking: Form 90. J Stud Alcohol Drugs 2007; 68: 615-8.
89. Scheurich A., Muller M. J., Anghelescu I., Lorch B., Dreher M., Hautzinger M. etal. Reliability and validity of the Form 90 interview. Eur Addict Res 2005; 11: 50-6.
90. Tonigan J. S., Miller W. R., Brown J. M. Reliability of Form 90: an instrument for assessing alcohol treatment outcome. J Stud Alcohol 1997; 58: 358-64.
91. Carroll K. M., Fenton L. R., Ball S. A., Nich C., Frankforter T. L., Shi J. etal. Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients: a randomized placebo controlled trial. Arch Gen Psychiatry 2004; 64: 264-72.
92. Fendrich M., Johnson T. P., Wislar J. S., Hubbell A., Spiehler V. The utility of drug testing in epidemiological research: results from a general population survey. Addiction 2004; 99: 197-208.
93. Somoza E., Somoza P., Lewis D., Li S.-H., Winhusen T., Chiang N. etal. The SRPK1 outcome measure for cocaine-dependence trials combines self-report with urine toxicology to determine weekly fractions of cocaine use days. Drug Alcohol Depend 2008; 93: 132-40.
94. Clifford P. R., Maisto S. A., Davis C. M. Alcohol treatment research assessment exposure subject reactivity effects: part I. Alcohol use and related consequences. J Stud Alcohol Drugs 2007; 68: 519-28.
95. Ling W., Amass L., Shoptaw S., Annon J. A., Babcock D., Brigham G. etal. A multi-center randomized trial of buprenorphine-naloxone and clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100: 1090-100.
96. Ball S. A., Van Horn D., Crits-Christoph P., Woody G. E., Farentinos C., Martino S. etal. Site matters: multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. J Consult Clin Psychol 2007; 75: 556-67.
97. Petry N. M., Peirce J. M., Stitzer M. L., Blaine J., Roll J. M., Cohen A. etal. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry 2005; 62: 1148-56.
98. Riggs P. D. New findings from a randomized controlled trial: osmotic-release methylphenidate (OROS-MPH) for ADHD in adolescents with substance use disorders. American Academy of Child and Adolescent Psychiatry (AACAP), 26-31 October. New York, NY. 2010. Available from: (accessed 17 June 2011; archived by Webcite at )
99. Nunes E. V. Web-delivery of evidence-based, psychosocial treatment for substance use disorders. In: National Institute on Drug Abuse Center for Clinical Trials Network. Bethesda, MD, 2010. Available from: (accessed 17 June 2011; archived by Webcite at )
100. Tiffany S. T., Friedman L., Greenfield S. F., Hasin D. S., Jackson R. Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction; in press; 2011.